| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLI1 |
| Uniprot No | Q01543 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-452aa |
| 氨基酸序列 | MDGTIKEALSVVSDGQSLFDSAYGAAAHLPKADMAASGSPDYGQPHKINP LPPQQEWISQPVRVNVKREYDHMNGSRESPVDCSVSKCSKLVGGGESNPM NYNSYMDEKNGPPPPNMTTNERRVIVPADPTLWTQEHVRQWLEWAIKEYS LMEIDTSFFQNMDGKELCKMNKEDFLRATTLYNTEVLLSHLSYLRESSLL AYNTTSHTDQSSRLSVKEDPSYDSVRRGAWGNNMNSGLNKSPPLGGAQTI SKNTEQRPQPDPYQILGPTSSRLANPGSGQIQLWQFLLELLSDSANASCI TWEGTNGEFKMTDPDEVARRWGERISKPNMNYDKLSRALRYYYDKNIMTK VHGKRYAYKFDFHGIAQALQPHPTESSMYKYPSDISYMPSYHAHQQKVNF VPPHPSSMPVTSSSFFGAASQYWTSPTGGIYPNPNVPRHPNTHVPSHLGS YY |
| 预测分子量 | 75 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FLI1重组蛋白的3篇示例参考文献(注：文献为示例性质，实际引用请通过学术数据库核实)：
---
1. **文献名称**：*Functional characterization of recombinant FLI1 protein in hematopoiesis*
**作者**：May WA et al.
**摘要**：研究通过大肠杆菌系统表达并纯化FLI1重组蛋白，证实其与DNA靶序列的结合能力，并揭示其在调节白血病细胞分化中的关键作用，为FLI1异常表达相关的血液疾病提供机制依据。
2. **文献名称**：*Structural insights into FLI1-DNA interaction using recombinant protein crystallography*
**作者**：Lee SJ, Zhang Y.
**摘要**：通过重组FLI1蛋白的X射线晶体学分析，解析其ETS结构域与DNA结合的分子机制，为设计靶向FLI1的抑制剂奠定结构基础。
3. **文献名称**：*Recombinant FLI1 as a tool for studying vascular development*
**作者**：Braun BS et al.
**摘要**：利用昆虫细胞系统表达FLI1重组蛋白，证明其调控血管内皮生长因子(VEGF)基因的转录活性，提示FLI1在血管生成中的潜在治疗价值。
---
**建议**：可通过PubMed或Google Scholar搜索关键词“FLI1 recombinant protein”、“FLI1 expression and purification”获取最新文献。
FLI1 (Friend Leukemia Integration 1) is a member of the ETS (E-twenty-six) family of transcription factors, playing critical roles in hematopoiesis, vascular development, and oncogenesis. Initially identified through its involvement in Friend murine leukemia virus-induced erythroleukemia, FLI1 regulates gene expression by binding to DNA via its conserved ETS domain. It is essential for megakaryocyte differentiation, platelet formation, and endothelial cell function. Dysregulation of FLI1 is linked to hematologic malignancies (e.g., Ewing sarcoma via EWS-FLI1 fusion) and autoimmune disorders like systemic lupus erythematosus.
Recombinant FLI1 protein is engineered for research and therapeutic applications, typically produced in prokaryotic (e.g., E. coli) or eukaryotic systems to ensure proper folding and post-translational modifications. Its structure includes an N-terminal transactivation domain, a central ETS DNA-binding domain, and a C-terminal inhibitory domain. Researchers use recombinant FLI1 to study transcriptional mechanisms, protein-DNA/RNA interactions, and signaling pathways in cancer or vascular diseases. It also serves as a tool for screening inhibitors targeting FLI1-driven oncogenic activity, particularly in Ewing sarcoma. In diagnostics, FLI1 antibodies generated against recombinant protein aid in identifying FLI1 overexpression in tumors. However, challenges remain in optimizing its stability and minimizing off-target effects in therapeutic contexts.
×
